Inventaire - your friends and communities are your best library

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

Author

Stephane Angers

Daniel-G. Bichet

1946 -

Michel Bouvier

1959 -

Published in: Journal of Clinical Investigation

Date of publication: April 1, 2000

Language: English

Main subject: molecular chaperone, AVP, pharmacology

Bibliographic databases:

Cites articles 35

Date

Title

Authors

1985

Assembly of asparagine-linked oligosaccharides
August 1, 1986

Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis
July 1, 1986

Binding of a specific ligand inhibits import of a purified precursor protein into mitochondria
January 1, 1987

Use of eukaryotic expression technology in the functional analysis of cloned genes
January 1, 1987

The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum
November 1, 1990

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
May 1, 1991

Mutant α subunits of Gi2 inhibit cyclic AMP accumulation

,
December 1, 1991

Chloride Conductance Expressed by ΔF508 and Other Mutant CFTRs In Xenopus Oocytes

,
December 1991

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
April 1, 1994

Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport
October 1995

Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus
November 1, 1995

A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist
December 15, 1996

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
June 25, 1996

Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors
June 1, 1996

Influence of molecular and chemical chaperones on protein folding
March 1, 1996

Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide
November 1, 1996

Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor
October 1, 1996

Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function
November 1, 1996

Functional characterization of five V2 vasopressin receptor gene mutations
November 1, 1997

Biochemical basis of partial nephrogenic diabetes insipidus phenotypes,Biochemical Basis of Partial Nephrogenic Diabetes Insipidus Phenotypes

,
September 1, 1997

Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication
June 1, 1997

An X-linked NDI mutation reveals a requirement for cell surface V2R expression
January 1, 1997

Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility

,
August 1, 1997

Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists,Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster α1B-adrenoceptor by ligands that act as inverse agonists
November 1, 1997

Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation

,
January 1, 1997

Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators
July 1, 1998

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors,5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]- [1,4]benzodiazepin-10(11H)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2Receptors
May 1, 1998

Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones
April 1, 1998

The molecular basis of nephrogenic diabetes insipidus
October 1, 1998

Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype

,
December 1, 1998

The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities
July 1, 1999

O-Glycosylation of the V2 vasopressin receptor

Article -

Welcome to inventaire

The library of your friends and communities

Learn more